Immutep Limited
IMM.AX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$33.9M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $33.90 Million |
|---|---|
| Enterprise Value | $-33,933,780.00 |
| Earnings per Share | $-0.05 |
| Beta | 2.3 |
| Outstanding Shares | 1,473,721,306 |
Return
| Return on Equity | -229.50% |
|---|---|
| Return on Assets | -169.59% |
| Return on Invested Capital | -217.89% |
Valuation & Multiples
| P/E Ratio | -0.43 |
|---|---|
| PEG | 4.04 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -1.56 |
| Enterprise Value to EBIT | 0.23 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.03 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 30, 2026
EPS Estimate
$-0.00
Consensus analyst estimateRevenue Estimate
$16.76 M
Consensus analyst estimateNext Earnings Call
Expected Date
February 25, 2027
EPS Estimate
$-0.01
Consensus analyst estimateRevenue Estimate
$2.00 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Immutep Limited
57 employees
CEO: Marc Voigt
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP32...